CMS Announces Selection of Drugs for Third Cycle of Medicare Drug Price Negotiation Program, Including First-Ever Part B Drugs
The UNGASS marked a shift in the overall drug policy discourse to highlight drugs the public health and human rights dimensions of the world drug problem and to achieve a better balance between supply reduction and public health measures. More than 36 million years of healthy life loss (DALY) were attributable to drug use in 2019. Among…